ACT Capital Management LLC Buys New Position in REGENXBIO Inc. $RGNX

ACT Capital Management LLC bought a new stake in REGENXBIO Inc. (NASDAQ:RGNX) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 82,500 shares of the biotechnology company’s stock, valued at approximately $1,188,000. REGENXBIO comprises about 1.0% of ACT Capital Management LLC’s holdings, making the stock its 22nd biggest holding.

Several other institutional investors have also recently made changes to their positions in RGNX. Aquatic Capital Management LLC bought a new position in shares of REGENXBIO during the 3rd quarter worth approximately $37,000. Jones Financial Companies Lllp boosted its stake in shares of REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,270 shares during the period. Captrust Financial Advisors bought a new position in shares of REGENXBIO during the 2nd quarter worth approximately $85,000. Prudential Financial Inc. bought a new position in shares of REGENXBIO during the 2nd quarter worth approximately $87,000. Finally, ProShare Advisors LLC bought a new position in shares of REGENXBIO during the 4th quarter worth approximately $155,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays reduced their target price on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. Morgan Stanley set a $16.00 price target on REGENXBIO in a research note on Friday, May 15th. HC Wainwright reduced their price target on REGENXBIO from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Finally, Bank of America reduced their price target on REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.55.

REGENXBIO Price Performance

RGNX opened at $7.90 on Thursday. The business has a fifty day simple moving average of $7.90 and a 200 day simple moving average of $10.10. The company has a market capitalization of $408.43 million, a PE ratio of -1.41 and a beta of 1.04. REGENXBIO Inc. has a 1 year low of $5.45 and a 1 year high of $16.19.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.36). The firm had revenue of $6.39 million during the quarter, compared to the consensus estimate of $25.84 million. REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. Equities analysts anticipate that REGENXBIO Inc. will post -3.69 earnings per share for the current fiscal year.

Insider Buying and Selling at REGENXBIO

In other news, insider Steve Pakola sold 15,309 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $11.02, for a total transaction of $168,705.18. Following the completion of the sale, the insider directly owned 232,617 shares in the company, valued at approximately $2,563,439.34. This represents a 6.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 14.22% of the company’s stock.

REGENXBIO Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.